anonymised individual patient-level data (AstraZeneca ltd)
90
Structured Review
AstraZeneca ltd
anonymised individual patient-level data
Anonymised Individual Patient Level Data, supplied by AstraZeneca ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anonymised+individual+patient-level+data/patient+level+data/pm37233868-184-19-0
Average 90 stars, based on 1 article reviews
Anonymised Individual Patient Level Data, supplied by AstraZeneca ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anonymised+individual+patient-level+data/patient+level+data/pm37233868-184-19-0
Average 90 stars, based on 1 article reviews
anonymised individual patient-level data - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
other:Article Title: Cost-Effectiveness Analysis of Biomarker Testing to Guide First-Line PARP Inhibitor Maintenance for Patients with Advanced Ovarian Cancer After Response to First-Line Platinum Chemotherapy in the USA. Article Snippet: Background Poly(ADP-ribose) polymerase inhibitor maintenance treatments are available for platinum-sensitive advanced ovarian cancer.. Olaparib (O) is available for BRCA mutation patients or in combination with bevacizumab (O+B) for patients with homologous recombination deficiency (HRD+); niraparib (N) is available for all patients.. Objective This study aimed to evaluate the cost effectiveness of biomarker testing and maintenance treatments (mTx) with poly(ADP-ribose) polymerase inhibitor in platinum-sensitive advanced ovarian cancer in the USA. |